mAbs

SJR Rank #1,353H-index: 117SJR: 2.065Best quartile: Q1Open AccessAPC: US$3,575Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

Taylor and Francis Ltd.

Country

United States

Type

journal

SJR by Edition

2022202500.551.11.652.2

Subject Categories

  • ImmunologyQ1
  • Immunology and AllergyQ1

Areas: Immunology and Microbiology · Medicine

Most published research topics

Monoclonal and Polyclonal Antibodies ResearchProtein purification and stabilityGlycosylation and Glycoproteins ResearchViral Infectious Diseases and Gene Expression in InsectsCAR-T cell therapy researchBiosimilars and Bioanalytical MethodsT-cell and B-cell ImmunologyHER2/EGFR in Cancer ResearchImmunotherapy and Immune ResponsesImmune Cell Function and Interaction

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs070140210280

Documents per Year

2022202503570105140

Detailed Information

ISSN

1942-0870, 1942-0862

SJR Best Quartile

Q1

Region

Northern America

Citations per Document (2 years)

7.59

References per Document

65.94

Coverage

2009-2026

Scope

mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics. Relevant topics include (but are not be limited to): Antibody engineering and selection Targets relevant to cancer, immune-mediated disorders, and other diseases Non-clinical studies of antibodies, e.g., mechanism of action studies, safety and efficacy studies in animals Manufacturing Clinical studies Regulatory review of antibody therapeutics Post-approval topics, e.g., pricing, reimbursement and markets Patents Emerging markets for antibody therapeutics, including China and India All submitted manuscripts are subjected to initial evaluation by the editorial staff, and, if found suitable for further consideration, manuscripts are sent to peer review by independent, anonymous expert referees.

Metrics from SCImago Journal Rank 2025. View on SCImago